Mucosa-associated microbiota alterations in primary sclerosing cholangitis(PSC)before and after liver transplantation-who is calling the shots?

Primary sclerosing cholangitis(PSC)is an immune-related chronic cholangiopathy associated with high rates of progression to liver cirrhosis and the need for liver transplantation.Since PSC is frequently associated with inflammatory bowel disease(IBD),several studies have investigated the role of the gut-liver axis in PSC and emerging evidence indicates that gut and bile microbiota are associated with the onset and progression of PSC[reviewed in(1)].

Assessment of morbidity and mortality after liver transplantation for primary sclerosing cholangitis

Primary sclerosing cholangitis(PSC)is a progressive liver disease that causes biliary inflammation,recurrent cholangitis,and liver fibrosis(1).Although there are therapeutic options that temporarily reduce the itching and jaundice caused by PSC,there is currently no effective definitive treatment.The rate of disease progression varies among individuals,but it ultimately leads to end-stage liver disease and necessitates liver transplantation(2).

Liver transplantation for primary sclerosing cholangitis-morbidities including disease recurrence

Primary sclerosing cholangitis(PSC)is one of the major diseases indicated for liver transplantation(LTx).There are some important points to be considered when discussing LTx for PSC,which makes it a unique etiology among liver transplant physicians.PSC often coexists with inflammatory bowel disease(IBD),mainly ulcerative colitis(UC),and patients with PSC are prone to develop colorectal cancer and cholangiocarcinoma both before and after LTx.

Primary sclerosing cholangitis and cholangiocarcinoma:the 2023 practice guidance and future perspectives

The 2023 practice guidance on primary sclerosing cholangitis(PSC)and cholangiocarcinoma(CCA)of the American Association for the Study of Liver Diseases(AASLD)came as a needful update to the previous 2010 guidelines on PSC,with a first-time inclusion of dedicated guidance on the diagnosis and management of CCA(1,2).This data-supported approach developed by consensus of an expert panel,provides guidance statements based on analytical review of the relevant literature.

Primary sclerosing cholangitis:A review and update

Primary sclerosing cholangitis(PSC)is a rare,chronic,cholestatic liver disease of uncertain etiology characterized biochemically by cholestasis and histologically and cholangiographically by fibroobliterative inflammation of the bile ducts.In a clinically significant proportion of patients,PSC progresses to cirrhosis,end-stage liver disease,and/or hepatobiliary cancer,though the disease course can be highly variable.Despite clinical trials of numerous pharmacotherapies over several decades,safe and effective medical therapy remains to be established.Liver transplantation is an option for select patients with severe complications of PSC,and its outcomes are generally favorable.Periodic surveillance testing for pre-as well as post-transplant patients is a cornerstone of preventive care and health maintenance.Here we provide an overview of PSC,including its epidemiology,etiopathogenesis,clinical features,associated disorders,surveillance,and emerging potential therapies.

Biliary endoscopy in the management of primary sclerosing cholangitis and its complications

Primary sclerosing cholangitis(PSC)is a chronic,idiopathic,cholestatic liver disease characterized by inflammation and fibrosis of the intrahepatic and/or extrahepatic bile ducts.It can affect individuals of all age groups and gender,has no established pharmacotherapy,and is associated with a variety of neoplastic(e.g.cholangiocarcinoma)and non-neoplastic(e.g.dominant strictures)hepatobiliary complications.Given these considerations,endoscopy plays a major role in the care of patients with PSC.In this review,we discuss and provide updates regarding endoscopic considerations in the management of hepatobiliary manifestations and complications of PSC.Where evidence is limited,we suggest pragmatic approaches based on currently available data and expert opinion.

Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist

Cholestatic liver diseases(CLDs)encompass a variety of disorders of abnormal bile formation and/or flow.CLDs often lead to progressive hepatic insult and injury and following the development of cirrhosis and associated complications.Many such complications are clinically silent until they manifest with severe sequelae,including but not limited to life-altering symptoms,metabolic disturbances,cirrhosis,and hepatobiliary diseases as well as other malignancies.Primary sclerosing cholangitis(PSC)and primary biliary cholangitis(PBC)are the most common CLDs,and both relate to mutual as well as unique complications.This review provides an overview of PSC and PBC,with a focus on preventive measures aimed to reduce the incidence and severity of disease-related complications.